Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence

详细信息    查看全文

• 作者：Siok Ching Chia ; Jeyakumar Henry ; Yee Ming Mok…
• 关键词：Schizophrenia ; Supplementation ; Symptoms ; Fatty acids ; Folate
• 刊名：Journal of Neural Transmission
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：122
• 期：12
• 页码：1721-1732
• 全文大小：462 KB
• 参考文献：Arvindakshan M, Ghate M, Ranjekarm PK, Evans DR, Mahadik SP (2003) Supplementation with a combination of 蠅-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62:195鈥?04CrossRef PubMed
  Assies J, Lieverse R, Vreken P, Wanders RJA, Dingemans PMJA, Linszen DH (2001) Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenia patients compared with a carefully matched control group. Biol Psychiatry 49:510鈥?22CrossRef PubMed
  Barch DM (2005) The relationships among cognition, motivation, and emotion in schizophrenia: how much and how little we know. Schizophr Bull 31(4):875鈥?81CrossRef PubMed
  Bentsen H, Osnes K, Refsum H, Solberg DK, B酶hmer T (2013) A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia. Transl Psychiatry 3(12):e335CrossRef PubMed PubMedCentral
  Carbon M, Correll CU (2014) Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 19(Suppl 1):38鈥?2PubMed
  Chue P, Lalonde JK (2014) Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatr Dis Treat 10:777鈥?89CrossRef PubMed PubMedCentral
  Dakhale GN, Khanzode SD, Khanzode SS, Saoji A (2005) Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology 182(4):494鈥?98CrossRef PubMed
  Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS et al (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166(6):675鈥?82CrossRef PubMed
  Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V (2013) The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 47(2):197鈥?07CrossRef PubMed
  Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ (2002) Randomised, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159(9):1596鈥?598CrossRef PubMed
  Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158(12):2071鈥?074CrossRef PubMed
  Fett AKJ, Viechtbauer W, Penn DL, van OsJ Krabbendam L (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 35(3):573鈥?88CrossRef PubMed
  Godfrey PSA, Toone BK, Carney MWP et al (1990) Enhancement of recovery from psychiatric illness by methylfolate. Lancet 336(8712):392鈥?95CrossRef PubMed
  Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in First-Episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64(10):1115鈥?122CrossRef PubMed
  Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, M枚ller HJ, WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14:2鈥?4CrossRef PubMed
  Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 127:41鈥?5CrossRef PubMed
  Horrobin DF (1999) The effects of antipsychotic drugs on membrane phospholipids: a possible novel mechanism of action of clozapine. In: Peet M, Glen I, Horrobin DF (eds) Phospholipid Spectr Dis Psychiatry. Marius Press, UK, pp 113鈥?17
  Huskisson E, Maggini S, Ruf M (2007) The influence of micronutrients on cognitive function and performance. J Int Med Res 35(1):1鈥?9CrossRef PubMed
  Insel TR (2010) Rethinking schizophrenia. Nature 468(7321):187鈥?93CrossRef PubMed
  Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, Jenner P, Halliwell B (1995) Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 49:359鈥?65CrossRef PubMed
  Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S (2010) Reduced folic acid, vitamin B 12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 175(1):47鈥?3CrossRef PubMed
  Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (2002) Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58(1):1鈥?0CrossRef PubMed
  Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of antipsychotic drugs. Psychol Med 10(01):55鈥?2CrossRef PubMed
  McCreadie RG, Kelly C, Connolly M, Williams S, Baxter G, Lean M, Paterson JR (2005) Dietary improvement in people with schizophrenia Randomised controlled trial. Br J Psychiatry 187(4):346鈥?51CrossRef PubMed
  Mellor JE, Laugharne JDE, Peet M (1996) Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol 11:39鈥?6CrossRef
  Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142(1):37鈥?6CrossRef PubMed
  Muntjewerff JW, Blom HJ (2005) Aberrant folate status in schizophrenic patients: what is the evidence. Prog Neuropsychopharmacol Biol Psychiatry 29(7):1133鈥?139CrossRef PubMed
  Parletta N, Milte CM, Meyer BJ (2013) Nutritional modulation of cognitive function and mental health. J Nutr Biochem 24(5):725鈥?43CrossRef PubMed
  Peet M (2008) Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 45(1):19鈥?5PubMed
  Peet M, Horrobin DF (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 36(1):7鈥?8CrossRef PubMed
  Peet M, Brind J, Ramchand CN, Shah S, Vankar GK (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49(3):243鈥?51CrossRef PubMed
  Rietjens IM, Boersma MG, de Haan L, Spenkelink B, Awad HM, Cnubben NH, van Zanden JJ, van der Woude H, Alink GM, Koeman JH (2002) The pro-oxidant chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids. Environ Toxicol Pharmacol 11(3):321鈥?33CrossRef PubMed
  Roffman JL, Lamberti S, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC (2013) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70(5):481鈥?89CrossRef PubMed PubMedCentral
  Shah S, Vankar GK, Telang SD, Ramchand CN, Peet M (1998) Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia. Schizophr Res 29:158CrossRef
  Sicras-Mainar A, Blanca-Tamayo M, Rejas-Guti茅rrez J, Navarro-Artieda R (2008) Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry 23(2):100鈥?08CrossRef PubMed
  Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandol E (2007) The impact of 蠅-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31:1493鈥?499CrossRef PubMed
  Strassnig M, Brar JS, Ganuli R (2005) Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr Res 76:343鈥?51CrossRef PubMed
  Sumiyoshi T, Matsui M, Itoh H, Higuchi Y, Arai H, Takamiya C, Kurachi M (2008) Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res 157:87鈥?3CrossRef PubMed
  van Rensburg SJ, Smuts CM, Hon D, Kidd M, van der Merwe S, Myburgh C, Oosthuizen P, Emsley R (2009) Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia. Metab Brain Dis 24(4):659鈥?72CrossRef PubMed
  Vaughan K, McConaghy N (1999) Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial. Aust N Z J Psychiatry 33(1):84鈥?8CrossRef PubMed
  
• 作者单位：Siok Ching Chia (1)
  Jeyakumar Henry (1)
  Yee Ming Mok (2)
  William G. Honer (3)
  Kang Sim (2)
  
  1. Clinical Nutrition Research Centre, Singapore Institute for Clinical Sciences, 14 Medical Drive, #07-02, Singapore, 117599, Singapore
  2. Institute of Mental Health/Woodbridge Hospital, 10, Buangkok View, Singapore, 539747, Singapore
  3. Jack Bell Chair in Schizophrenia, Department of Psychiatry, Director, Institute of Mental Health, University of British Columbia, Detwiller Pavilion, 2255 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurology
  Pharmacology and Toxicology
  Psychiatry
  
• 出版者：Springer Wien
• ISSN：1435-1463

文摘

Current psychopharmacological approaches to reduce psychotic phenomenology in schizophrenia are associated with adverse effects including extrapyramidal and metabolic side effects. In view of the emerging data on nutritional supplementation interventions in schizophrenia which are not entirely consistent, we aimed to review existent studies focusing on fatty acid and vitamin interventions and summarise current evidence on such nutritional supplementations in schizophrenia. We searched the digital databases (ScienceDirect, Scopus, SpringerLINK, PubMed/Medline) for relevant studies pertaining to fatty acid and vitamin supplementation interventions in the management of psychotic symptoms in schizophrenia up to February 2015. Overall, there were more studies conducted on fatty acid over vitamin supplementations in patients with schizophrenia. There were more positive findings in support of fatty acid supplementation compared with vitamin supplementation in the context of specific intervention features (dose of nutrient supplementation, single versus combination nutritional interventions, specific antipsychotic), subject features (older age, long duration of illness, baseline polyunsaturated fatty acid levels) and clinical outcomes (improvements of psychotic symptoms and/or extrapyramidal side effects from antipsychotics). However, investigations of both supplementation modalities were limited by relatively small study sample sizes, short study duration, which precluded further segmentation of impact on more diverse patient subtypes and symptom profiles. Future studies may consider examining larger samples over a longer time period, recruiting younger subjects with shorter duration of illness, examination of different clinical features including specific cognitive domains, and use of single versus combination nutritional interventions. Keywords Schizophrenia Supplementation Symptoms Fatty acids Folate